Australia: Bionomics reveals plans for US IPO following exercise to improve balance sheet

Bionomics, a clinical stage biopharmaceutical company, is planning an IPO of American Depositary Shares (ADSs) in the United States and a concurrent listing on Nasdaq. The number of ADSs and price of the proposed offering have not yet been determined. Bionomics is dedicated to developing treatments for central nervous system disorders such as anxiety, depression and…

You must be a HMI Subscriber to view this content.

Subscribe Now »